Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer J Clin. 2018;68(6):394–424.
Google Scholar
Jensen EV. On the mechanism of estrogen action. Perspect Biol Med. 1962;6(1):47–60.
CAS
PubMed
Google Scholar
Park YR, Lee J, Jung JH, Kim WW, Park CS, Lee RK, Chae YS, Lee SJ, Park JY, Park JY, et al. Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer. Asian J Surg. 2020;43(3):467–75.
PubMed
Google Scholar
Kumar M, Salem K, Tevaarwerk AJ, Strigel RM, Fowler AM. Recent advances in imaging steroid hormone receptors in breast cancer. J Nucl Med. 2020;61(2):172–6.
PubMed
Google Scholar
Kruchten MV, Glaudemans AWJM, Vries EFJD, Beets-Tan RGH, Schroder C, Dierckx R, Vries EGED, Hospers GAP. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53(2):182–90.
PubMed
Google Scholar
Kuiper G, Enmark E, PeltoHuikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93(12):5925–30.
CAS
PubMed
PubMed Central
Google Scholar
Bhattacharjee A, Hossain MU, Chowdhury ZM, Rahman SMA, Bhuyan ZA, Salimullah M, Keya CA. Insight of druggable cannabinoids against estrogen receptor beta in breast cancer. J Biomol Struct Dyn. 2020:1–10.
Park H, McEachon JD, Pollock JA. Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands. Bioorg Med Chem. 2019;27(10):2075–82.
CAS
PubMed
Google Scholar
Crandall DL, Busler DE, Novak TJ, Weber RV, Kral JG. Identification of estrogen receptor beta RNA in human breast and abdominal subcutaneous adipose tissue. Biochem Biophys Res Commun. 1998;248(3):523–6.
CAS
PubMed
Google Scholar
Kuiper GG, Shughrue PJ, Merchenthaler I, Gustafsson JA. The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol. 1998;19(4):253–86.
CAS
PubMed
Google Scholar
Balla B, Sarvari M, Kosa JP, Kocsis-Deak B, Tobias B, Arvai K, Takacs I, Podani J, Liposits Z, Lakatos P. Long-term selective estrogen receptor-beta agonist treatment modulates gene expression in bone and bone marrow of ovariectomized rats. J Steroid Biochem Mol Biol. 2019;4(188):185–94.
Google Scholar
Liu JYH, Lin G, Fang MR, Rudd JA. Localization of estrogen receptor ER alpha, ER beta and GPR30 on myenteric neurons of the gastrointestinal tract and their role in motility. Gen Comp Endocrinol. 2019;1(272):63–75.
Google Scholar
Tamer SA, Yildirim A, Arabaci S, Ciftci S, Akin S, Sari E, Koroglu MK, Ercan F, Yuksel M, Cevik O, et al. Treatment with estrogen receptor agonist ER beta improves torsion-induced oxidative testis injury in rats. Life Sci. 2019;1(222):203–11.
Google Scholar
Le Moene O, Stavarache M, Ogawa S, Musatov S, Agmo A. Estrogen receptors alpha and beta in the central amygdala and the ventromedial nucleus of the hypothalamus: Sociosexual behaviors, fear and arousal in female rats during emotionally challenging events. Behav Brain Res. 2019;23(367):128–42.
Google Scholar
Kim H, Park J, Leem H, Cho M, Yoon JH, Maeng HJ, Lee Y. Rhododendrin-induced RNF146 expression via estrogen receptor beta activation is cytoprotective against 6-OHDA-induced oxidative stress. Int J Mol Sci. 2019;20(7):e1772.
PubMed
Google Scholar
Sang JH, Jung SY, Wu SP, Hawkins SM, Park M, Kyo S, Jun Q, Lydon J, Tsai S, Tsai M, et al. Estrogen receptor β modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell. 2015;163(4):960–74.
Du M, Shan J, Feng A, Schmull S, Gu J, Song X. Oestrogen receptor beta activation protects against myocardial infarction via Notch1 signalling. Cardiovasc Drugs Ther. 2020;34(2):165–78.
CAS
PubMed
PubMed Central
Google Scholar
Ofosu W, Mohamed D, Corcoran O, Ojo O. The role of oestrogen receptor beta (ERβ) in the aetiology and treatment of type 2 diabetes mellitus. Curr Diabetes Rev. 2019;15(2):100–4.
CAS
PubMed
Google Scholar
Bharathi C, Anupama D, Pratibha N, Venkateshwari A. Impact of genetic variants in estrogen receptor-beta gene in the etiology of uterine leiomyomas. J Reprod Infertil. 2019;20(3):151–60.
PubMed
PubMed Central
Google Scholar
Ibrahim A, Hugerth LW, Hases L, Saxena A, Seifert M, Thomas Q, Gustafsson JA, Engstrand L, Williams C. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int J Cancer. 2019;144(12):3086–98.
CAS
PubMed
PubMed Central
Google Scholar
Santti K, Ihalainen H, Ronty M, Karlsson C, Haglund C, Sampo M, Tarkkanen M, Blomqvist C. Estrogen receptor beta expression correlates with proliferation in desmoid tumors. J Surg Oncol. 2019;119(7):873–9.
CAS
PubMed
Google Scholar
Majumdar S, Rinaldi JC, Malhotra NR, Xie L, Hu DP, Gauntner TD, Grewal HS, Hu WY, Kim SH, Katzenellenbogen JA, et al. Differential actions of estrogen receptor alpha and beta via nongenomic signaling in human prostate stem and progenitor cells. Endocrinology. 2019;160(11):2692–708.
PubMed
PubMed Central
Google Scholar
Liang L, Williams MD, Bell D. Expression of PTEN, androgen receptor, HER2/neu, cytokeratin 5/6, estrogen receptor-beta, HMGA2, and PLAG1 in salivary duct carcinoma. Head Neck Pathol. 2019;13(4):529–34.
PubMed
Google Scholar
Litwiniuk MM, Roznowski K, Filas V, Godlewski DD, Stawicka M, Kaleta R, Breborowicz J. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer. 2008;13(8):e100.
Google Scholar
Dago DN, Scafoglio C, Rinaldi A, Memoli D, Giurato G, Nassa G, Ravo M, Rizzo F, Tarallo R, Weisz A. Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells. BMC Genomics. 2015;9(16):367.
Google Scholar
Ruddy SC, Lau R, Cabrita MA, McGregor C, McKay BC, Murphy LC, Wright JS, Durst T, Pratt MA. Preferential estrogen receptor beta ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy. Mol Cancer Ther. 2014;13(7):1882–93.
CAS
PubMed
Google Scholar
Kuiper G, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138(3):863–70.
CAS
PubMed
Google Scholar
Hall JM, McDonnell DP, Korach KS. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol. 2002;16(3):469–86.
CAS
PubMed
Google Scholar
Hawse JR, Carter JM, Aspros KGM, Bruinsma ES, Koepplin JW, Negron V, Subramaniam M, Ingle JN, Rech KL, Goetz MP. Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues. Breast Cancer Res Treat. 2020;179(1):241–9.
CAS
PubMed
Google Scholar
Elebro K, Borgquist S, Rosendahl AH, Markkula A, Simonsson M, Jirstrom K, Rose C, Ingvar C, Jernstrom H. High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients-results from a population-based breast cancer cohort. Clin Cancer Res. 2017;23(3):766–77.
CAS
PubMed
Google Scholar
Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' health study. Mod Pathol. 2010;23(2):197–204.
CAS
PubMed
Google Scholar
Girault I, Andrieu C, Tozlu S, Spyratos F, Bieche I, Lidereau R. Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett. 2004;215(1):101–12.
CAS
PubMed
Google Scholar
Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat. 2002;71(3):249–55.
CAS
PubMed
Google Scholar
Altundag O, Altundag K, Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses. 2004;63(4):684–7.
CAS
PubMed
Google Scholar
Mandusic V, Dimitrijevic B, Nikolic-Vukosavljevic D, Neskovic-Konstantinovic Z, Kanjer K, Hamann U. Different associations of estrogen receptor beta isoforms, ERbeta1 and ERbeta2, expression levels with tumor size and survival in early- and late-onset breast cancer. Cancer Lett. 2012;321(1):73–9.
CAS
PubMed
Google Scholar
Abbasi S. Estrogen receptor-beta gene polymorphism in women with breast cancer at the imam Khomeini hospital complex, Iran. BMC Med Genet. 2010;7(11):e109.
Google Scholar
Yu KD, Rao NY, Chen AX, Fan L, Yang C, Shao ZM. A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res Treat. 2011;126(1):37–45.
CAS
PubMed
Google Scholar
Xia W, Wang T, Sun D, Mao W, Xie X. Association of estrogen receptor-beta (ESR2) polymorphism and cancer risk: a meta-analysis. Eur J Gynaecol Oncol. 2016;37(4):530–8.
PubMed
Google Scholar
Chen L, Liang Y, Qiu J, Zhang L, Chen X, Luo X, Jiang J. Significance of rs1271572 in the estrogen receptor beta gene promoter and its correlation with breast cancer in a southwestern Chinese population. J Biomed Sci. 2013;20:32.
PubMed
PubMed Central
Google Scholar
Murphy LC, Leygue E. The role of estrogen receptor-beta in breast cancer. Semin Reprod Med. 2012;30(1):5–13.
CAS
PubMed
Google Scholar
Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004;10(22):7490–9.
CAS
PubMed
Google Scholar
de Cremoux P, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon MF, De Rycke Y, Asselain B, Magdelenat H. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol. 2002;64(3):507–15.
PubMed
Google Scholar
Stefanou D, Batistatou A, Briasoulis E, Arkoumani E, Agnantis NJ. Estrogen receptor beta (ERbeta) expression in breast carcinomas is not correlated with estrogen receptor alpha (ERalpha) and prognosis: the Greek experience. Eur J Gynaecol Oncol. 2004;25(4):457–61.
CAS
PubMed
Google Scholar
Chang J, Liu J, Li H, Li J, Mu Y, Feng B. Expression of ERbeta gene in breast carcinoma and the relevance in neoadjuvant therapy. Oncol Lett. 2017;13(3):1641–6.
CAS
PubMed
PubMed Central
Google Scholar
Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer. 2013;18(13):425.
Google Scholar
Oueslati M, Bittaieb I, Sassi N, Jemaa AB, Gamoudi A, Rahal K, Oueslati R. ERalpha and ERbeta co-expression: an indicator of aggressive tumors and hormonal sensitivity. Oncol Lett. 2017;14(2):1675–82.
PubMed
PubMed Central
Google Scholar
Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 2012;19(9):3107–15.
PubMed
Google Scholar
Guo L, Zhang Y, Zhang W, Yilamu D. Correlation between estrogen receptor beta expression and the curative effect of endocrine therapy in breast cancer patients. Exp Ther Med. 2014;7(6):1568–72.
PubMed
PubMed Central
Google Scholar
Guo L, Zhang YU, Yilamu D, Liu S, Guo C. ERbeta overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERalpha-positive breast cancer patients. Oncol Lett. 2016;11(2):1531–6.
CAS
PubMed
PubMed Central
Google Scholar
Yan M, Rayoo M, Takano EA, Fox SB. Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat. 2011;126(2):395–405.
CAS
PubMed
Google Scholar
Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018;9(74):33912–30.
PubMed
PubMed Central
Google Scholar
Wisinski KB, Xu W, Tevaarwerk AJ, Saha S, Kim K, Traynor A, Dietrich L, Hegeman R, Patel D, Blank J, et al. Targeting estrogen receptor beta in a phase 2 study of high-dose estradiol in metastatic triple-negative breast cancer: a Wisconsin oncology network study. Clin Breast Cancer. 2016;16(4):256–61.
CAS
PubMed
PubMed Central
Google Scholar
Shanle EK, Onitilo AA, Huang W, Kim K, Zang C, Engel JM, Xu W, Wisinski KB. Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer. Am J Transl Res. 2015;7(7):1246–59.
CAS
PubMed
PubMed Central
Google Scholar
Guo L, Zhu Q, Aisimutuola M, Yilamu D, Liu S, Jakulin A. Expression and prognostic value of estrogen receptor beta in patients with triple-negative and triple-positive breast cancer. Exp Ther Med. 2015;9(6):2147–50.
CAS
PubMed
PubMed Central
Google Scholar
Hamilton N, Marquez-Garban D, Mah V, Fernando G, Elshimali Y, Garban H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Biologic roles of estrogen receptor-beta and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015;2015:e925703.
Google Scholar
Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X. ERbeta1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152(2):255–69.
CAS
PubMed
Google Scholar
Motomura K, Ishitobi M, Komoike Y, Koyama H, Nagase H, Inaji H, Noguchi S. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology. 2010;79(1–2):55–61.
CAS
PubMed
Google Scholar
Hamilton-Burke W, Coleman L, Cummings M, Green CA, Holliday DL, Horgan K, Maraqa L, Peter MB, Pollock S, Shaaban AM, et al. Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol. 2010;177(3):1079–86.
CAS
PubMed
PubMed Central
Google Scholar
Lam HM, Suresh Babu CV, Wang J, Yuan Y, Lam YW, Ho SM, Leung YK. Phosphorylation of human estrogen receptor-beta at serine 105 inhibits breast cancer cell migration and invasion. Mol Cell Endocrinol. 2012;358(1):27–35.
CAS
PubMed
PubMed Central
Google Scholar
Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999;59(21):5421–4.
CAS
PubMed
Google Scholar
Pons DG, Torrens-Mas M, Nadal-Serrano M, Sastre-Serra J, Roca P, Oliver J. The presence of estrogen receptor beta modulates the response of breast cancer cells to therapeutic agents. Int J Biochem Cell Biol. 2015;66:85–94.
CAS
PubMed
Google Scholar
Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 2011;13(2):R27.
CAS
PubMed
PubMed Central
Google Scholar
Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013;32(27):3274–85.
CAS
PubMed
Google Scholar
Ivanova MM, Luken KH, Zimmer AS, Lenzo FL, Smith RJ, Arteel MW, Kollenberg TJ, Mattingly KA, Klinge CM. Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites. FASEB J. 2011;25(4):1402–16.
CAS
PubMed
PubMed Central
Google Scholar
Lindberg K, Helguero LA, Omoto Y, Gustafsson JA, Haldosen LA. Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13(2):R43.
CAS
PubMed
PubMed Central
Google Scholar
Treeck O, Lattrich C, Springwald A, Ortmann O. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat. 2010;120(3):557–65.
CAS
PubMed
Google Scholar
Niu XL, Wang Y, Yao Z, Duan H, Li Z, Liu W, Zhang H, Deng WM. Autocrine interferon-gamma may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor beta subtype. Oncol Rep. 2015;34(6):3120–30.
CAS
PubMed
Google Scholar
Pitta CA, Papageorgis P, Charalambous C, Constantinou AI. Reversal of ER-beta silencing by chromatin modifying agents overrides acquired tamoxifen resistance. Cancer Lett. 2013;337(2):167–76.
CAS
PubMed
Google Scholar
Jiang H, Fan J, Cheng L, Hu P, Liu R. The anticancer activity of genistein is increased in estrogen receptor beta 1-positive breast cancer cells. Onco Targets Ther. 2018;11:8153–63.
CAS
PubMed
PubMed Central
Google Scholar
Lee MT, Ho SM, Tarapore P, Chung I, Leung YK. Estrogen receptor beta isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12. Neoplasia. 2013;15(11):1262–71.
CAS
PubMed
PubMed Central
Google Scholar
Zheng N, Liu L, Liu W, Zhang P, Huang H, Zang L, Hayashi T, Tashiro S, Onodera S, Xia M, et al. ERbeta up-regulation was involved in silibinin-induced growth inhibition of human breast cancer MCF-7 cells. Arch Biochem Biophys. 2016;1(591):141–9.
Google Scholar
Greish K, Nehoff H, Bahman F, Pritchard T, Taurin S. Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-beta and epidermal growth factor receptor. J Drug Target. 2019;27(8):903–16.
CAS
PubMed
Google Scholar
Tu Z, Li H, Ma Y, Tang B, Tian J, Akers W, Achilefu S, Gu Y. The enhanced antiproliferative response to combined treatment of trichostatin a with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor beta expression. Mol Cell Biochem. 2012;366(1–2):111–22.
CAS
PubMed
Google Scholar
Anestis A, Sarantis P, Theocharis S, Zoi I, Tryfonopoulos D, Korogiannos A, Koumarianou A, Xingi E, Thomaidou D, Kontos M, et al. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer. J Cancer Res Clin Oncol. 2019;145(5):1221–33.
CAS
PubMed
Google Scholar
Dall GV, Hawthorne S, Seyed-Razavi Y, Vieusseux J, Wu W, Gustafsson JA, Byrne D, Murphy L, Risbridger GP, Britt KL. Estrogen receptor subtypes dictate the proliferative nature of the mammary gland. J Endocrinol. 2018;237(3):323–36.
CAS
PubMed
Google Scholar
Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006;147(10):4831–42.
CAS
PubMed
Google Scholar
Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, et al. Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat. 2012;134(2):569–81.
CAS
PubMed
PubMed Central
Google Scholar
Lee YH, Sun Y, Gerweck LE, Glickman RD. Regulation of DNA damage response by estrogen receptor beta-mediated inhibition of breast cancer associated gene 2. Biomedicines. 2015;3(2):182–200.
CAS
PubMed
PubMed Central
Google Scholar
Sastre-Serra J, Nadal-Serrano M, Pons DG, Valle A, Garau I, Garcia-Bonafe M, Oliver J, Roca P. The oxidative stress in breast tumors of postmenopausal women is ERalpha/ERbeta ratio dependent. Free Radic Biol Med. 2013;8(61):11–7.
Google Scholar
Bussink J, van der Kogel AJ, Kaanders J. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008;9(3):288–96.
CAS
PubMed
Google Scholar
Treeck O, Schuler-Toprak S, Skrzypczak M, Weber F, Ortmann O. Knockdown of PTEN decreases expression of estrogen receptor beta and tamoxifen sensitivity of human breast cancer cells. Steroids. 2020;153:e108521.
Google Scholar
Sanchez M, Picard N, Sauve K, Tremblay A. Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene. 2013;32(1):117–26.
CAS
PubMed
Google Scholar
Zhao L, Huang S, Mei S, Yang Z, Xu L, Zhou N, Yang Q, Shen Q, Wang W, Le X, et al. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proc Natl Acad Sci U S A. 2018;115(16):E3673–e81.
CAS
PubMed
PubMed Central
Google Scholar
Hinsche O, Girgert R, Emons G, Grundker C. Estrogen receptor beta selective agonists reduce invasiveness of triple-negative breast cancer cells. Int J Oncol. 2015;46(2):878–84.
CAS
PubMed
Google Scholar
Song P, Li Y, Dong Y, Liang Y, Qu H, Qi D, Lu Y, Jin X, Guo Y, Jia Y, et al. Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. J Exp Clin Cancer Res. 2019;38(1):354.
PubMed
PubMed Central
Google Scholar
Piperigkou Z, Bouris P, Onisto M, Franchi M, Kletsas D, Theocharis AD, Karamanos NK. Estrogen receptor beta modulates breast cancer cells functional properties, signaling and expression of matrix molecules. Matrix Biol. 2016;12(56):4–23.
Google Scholar
Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, et al. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012;14(6):R148.
CAS
PubMed
PubMed Central
Google Scholar
Song W, Tang L, Xu Y, Sun Q, Yang F, Guan X. ERbeta1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1. J Exp Clin Cancer Res. 2017;36(1):75.
PubMed
PubMed Central
Google Scholar
Reese JM, Bruinsma ES, Nelson AW, Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V, Monroe DG, et al. ERbeta-mediated induction of cystatins results in suppression of TGFbeta signaling and inhibition of triple-negative breast cancer metastasis. Proc Natl Acad Sci U S A. 2018;115(41):E9580–e9.
CAS
PubMed
PubMed Central
Google Scholar
Schuler-Toprak S, Haring J, Inwald EC, Moehle C, Ortmann O, Treeck O. Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer. 2016;16(1):951.
PubMed
PubMed Central
Google Scholar
Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006;66(23):11207–13.
CAS
PubMed
Google Scholar
Lim W, Park Y, Cho J, Park C, Park J, Park YK, Park H, Lee Y. Estrogen receptor beta inhibits transcriptional activity of hypoxia inducible factor-1 through the downregulation of arylhydrocarbon receptor nuclear translocator. Breast Cancer Res. 2011;13(2):R32.
CAS
PubMed
PubMed Central
Google Scholar
Park C, Lee Y. Overexpression of ERbeta is sufficient to inhibit hypoxia-inducible factor-1 transactivation. Biochem Biophys Res Commun. 2014;450(1):261–6.
CAS
PubMed
Google Scholar
Lindberg K, Strom A, Lock JG, Gustafsson JA, Haldosen LA, Helguero LA. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol. 2010;222(1):156–67.
CAS
PubMed
Google Scholar
Ma L, Liu Y, Geng C, Qi X, Jiang J. Estrogen receptor beta inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int J Oncol. 2013;42(6):1993–2000.
CAS
PubMed
Google Scholar
Nair HB, Kirma NB, Ganapathy M, Vadlamudi RK, Tekmal RR. Estrogen receptor-beta activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. Steroids. 2011;76(8):792–6.
CAS
PubMed
Google Scholar
Shanle EK, Zhao Z, Hawse J, Wisinski K, Keles S, Yuan M, Xu W. Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells. Mol Endocrinol. 2013;27(10):1762–75.
CAS
PubMed
PubMed Central
Google Scholar
Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat. 2008;109(2):241–50.
CAS
PubMed
Google Scholar
Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64(1):423–8.
CAS
PubMed
Google Scholar
Reese JM, Bruinsma ES, Monroe DG, Negron V, Suman VJ, Ingle JN, Goetz MP, Hawse JR. ERbeta inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. Oncotarget. 2017;8(57):96506–21.
PubMed
PubMed Central
Google Scholar
Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, Leitman DC. Estrogen receptor beta causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat. 2011;129(3):777–84.
CAS
PubMed
Google Scholar
Sastre-Serra J, Nadal-Serrano M, Pons DG, Roca P, Oliver J. The over-expression of ERbeta modifies estradiol effects on mitochondrial dynamics in breast cancer cell line. Int J Biochem Cell Biol. 2013;45(7):1509–15.
CAS
PubMed
Google Scholar
Zhou Z, Zhou J, Du Y. Estrogen receptor beta interacts and colocalizes with HADHB in mitochondria. Biochem Biophys Res Commun. 2012;427(2):305–8.
CAS
PubMed
PubMed Central
Google Scholar
Koyama S, Wada-Hiraike O, Nakagawa S, Tanikawa M, Hiraike H, Miyamoto Y, Sone K, Oda K, Fukuhara H, Nakagawa K, et al. Repression of estrogen receptor beta function by putative tumor suppressor DBC1. Biochem Biophys Res Commun. 2010;392(3):357–62.
CAS
PubMed
Google Scholar
Chen L, Qiu J, Yang C, Yang X, Chen X, Jiang J, Luo X. Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells. Cancer Lett. 2009;278(2):210–9.
CAS
PubMed
Google Scholar
Picard N, Caron V, Bilodeau S, Sanchez M, Mascle X, Aubry M, Tremblay A. Identification of estrogen receptor beta as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3beta. Mol Cell Biol. 2012;32(14):2709–21.
CAS
PubMed
PubMed Central
Google Scholar
Tarallo R, Giurato G, Bruno G, Ravo M, Rizzo F, Salvati A, Ricciardi L, Marchese G, Cordella A, Rocco T, et al. The nuclear receptor ERbeta engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading. Genome Biol. 2017;18(1):189.
PubMed
PubMed Central
Google Scholar
Alexandrova E, Giurato G, Saggese P, Pecoraro G, Lamberti J, Ravo M, Rizzo F, Rocco D, Tarallo R, Nyman TA, et al. Interaction proteomics identifies ERbeta association with chromatin repressive complexes to inhibit cholesterol biosynthesis and exert an oncosuppressive role in triple-negative breast cancer. Mol Cell Proteomics. 2020;19(2):245–60.
CAS
PubMed
Google Scholar
Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, Dahlman-Wright K. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene. 2003;22(48):7600–6.
CAS
PubMed
Google Scholar
Gao L, Qi X, Hu K, Zhu R, Xu W, Sun S, Zhang L, Yang X, Hua B, Liu G. Estrogen receptor beta promoter methylation: a potential indicator of malignant changes in breast cancer. Arch Med Sci. 2016;12(1):129–36.
CAS
PubMed
PubMed Central
Google Scholar
Bozovic A, Markicevic M, Dimitrijevic B, Jovanovic Cupic S, Krajnovic M, Lukic S, Mandusic V. Potential clinical significance of ERbeta ON promoter methylation in sporadic breast cancer. Med Oncol. 2013;30(3):642.
PubMed
Google Scholar
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.
CAS
PubMed
Google Scholar
Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, Shaaban AM, Smith L, Speirs V. Estrogen receptor beta1 expression is regulated by miR-92 in breast cancer. Cancer Res. 2010;70(11):4778–84.
CAS
PubMed
PubMed Central
Google Scholar
Paris O, Ferraro L, Grober OM, Ravo M, De Filippo MR, Giurato G, Nassa G, Tarallo R, Cantarella C, Rizzo F, et al. Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer. Oncogene. 2012;31(38):4196–206.
CAS
PubMed
Google Scholar
Chen J, Zhao X, Ye Y, Wang Y, Tian J. Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin. Cell Physiol Biochem. 2013;32(6):1790–7.
CAS
PubMed
Google Scholar
Piperigkou Z, Franchi M, Gotte M, Karamanos NK. Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer. Matrix Biol. 2017;12(64):94–111.
Google Scholar
Nassa G, Tarallo R, Giurato G, De Filippo MR, Ravo M, Rizzo F, Stellato C, Ambrosino C, Baumann M, Lietzen N, et al. Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor beta via microRNAs. Mol Cell Proteomics. 2014;13(4):1076–90.
CAS
PubMed
PubMed Central
Google Scholar
Alexandrova E, Lamberti J, Saggese P, Pecoraro G, Memoli D, Cappa VM, Ravo M, Iorio R, Tarallo R, Rizzo F, et al. Small non-coding RNA profiling identifies miR-181a-5p as a mediator of estrogen receptor beta-induced inhibition of cholesterol biosynthesis in triple-negative breast cancer. Cells. 2020;9(4):874.
Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, Lanari C, Helguero LA. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene. 2013;32(19):2390–402.
CAS
PubMed
Google Scholar
Bado I, Pham E, Soibam B, Nikolos F, Gustafsson JA, Thomas C. ERbeta alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. Oncotarget. 2018;9(32):22509–22.
PubMed
PubMed Central
Google Scholar
Bado I, Nikolos F, Rajapaksa G, Wu W, Castaneda J, Krishnamurthy S, Webb P, Gustafsson JA, Thomas C. Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. Breast Cancer Res. 2017;19(1):79.
PubMed
PubMed Central
Google Scholar
Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Borresen-Dale AL, et al. TP53 status as a determinant of pro- vs anti-tumorigenic effects of estrogen receptor-beta in breast cancer. J Natl Cancer Inst. 2019;111(11):1202–15.
PubMed
PubMed Central
Google Scholar
Bado I, Nikolos F, Rajapaksa G, Gustafsson JA, Thomas C. ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget. 2016;7(12):13599–611.
PubMed
PubMed Central
Google Scholar
Thomas CG, Strom A, Lindberg K, Gustafsson JA. Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res Treat. 2011;127(2):417–27.
CAS
PubMed
Google Scholar
Lu W, Katzenellenbogen BS. Estrogen receptor-beta modulation of the ERalpha-p53 loop regulating gene expression, proliferation, and apoptosis in breast cancer. Horm Cancer. 2017;8(4):230–42.
CAS
PubMed
PubMed Central
Google Scholar
Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, Pillai S, Lam AKY, Gopalan V. Hereditary breast cancer; genetic penetrance and current status with BRCA. J Cell Physiol. 2019;234(5):5741–50.
CAS
PubMed
Google Scholar
Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM. The role of BRCA1/2 in hereditary and familial breast and ovarian cancers. Mol Genet Genom Med. 2019;7(9):7.
Google Scholar
Litwiniuk MM, Roznowski K, Filas V, Godlewski DD, Stawicka M, Kaleta R, Breborowicz J. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer. 2008;8:8.
Google Scholar
Chen JQ, Russo J. ERα-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009;1796(2):162–75.
CAS
PubMed
PubMed Central
Google Scholar
Qi F, Qin WX, Zang YS. Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways. Oncol Lett. 2019;17(3):2905–14.
CAS
PubMed
PubMed Central
Google Scholar
Li Y, Li S, Meng X, Gan RY, Zhang JJ, Li HB. Dietary natural products for prevention and treatment of breast Cancer. Nutrients. 2017;9(7):38.
Google Scholar
Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. Soy food intake and breast Cancer survival. Jama-J Am Med Assoc. 2009;302(22):2437–43.
Google Scholar
Douglas CC, Johnson SA, Arjmandi BH. Soy and its Isoflavones: the truth behind the science in breast Cancer. Anticancer Agents Med Chem. 2013;13(8):1178–87.
CAS
PubMed
Google Scholar
Chrzan BG, Bradford PG. Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res. 2010;51(2):171–7.
Google Scholar
Privat M, Aubel C, Arnould S, Communal Y, Ferrara M, Bignon YJ. Breast cancer cell response to genistein is conditioned by BRCA1 mutations. Biochem Biophys Res Commun. 2009;379(3):785–9.
CAS
PubMed
Google Scholar
Lattrich C, Stegerer A, Haring J, Schuler S, Ortmann O, Treeck O. Estrogen receptor beta agonists affect growth and gene expression of human breast cancer cell lines. Steroids. 2013;78(2):195–202.
CAS
PubMed
Google Scholar